Menu
Recruiting NCT06489119

Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease (MOOP-CAD)

— Observational Coronary Artery Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Coronary Artery Disease. Basic parameters: 18 years — 85 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Single-cell Multi-omics Analyses of OCT-diagnosed Plaque Subtypes in Coronary Artery Disease - a Prospective, Observational Study

Overview

The MOOP-CAD study program characterizes, for the first time, the pathophysiological processes and molecular mechanisms of coronary atherosclerotic plaque progression by combining in vivo intravascular imaging techniques with circulating immune single-cell multi-omics analysis. In this study, the investigators evaluate the imaging characteristics of coronary plaques by optical coherence tomography (OCT) and invasive angiography, and study the correlation between plaque characteristics and the multi-omics immune characteristic profiles.

Primary outcome measures

  • Incidence of MACE [Time frame: 1 year following hospital discharge]
Secondary outcome measures (3)
  • Incidence of SCD [Time frame: 1 year following hospital discharge]
  • Incidence of nonfatal myocardial infarction [Time frame: 1 year following hospital discharge]
  • Incidence of target vessel revascularization [Time frame: 1 year following hospital discharge]

Eligibility criteria

Inclusion criteria

  • Male or female, Age ≥ 18 years and ≤ 85 years.
  • Ability to understand the requirements of the study and to provide informed consent.

Control group:

Patients with coronary angiographic diameter stenosis <20%.

Stable plaque group:

  • Have been clinically stable for at least 6 months.
  • Presence of ≥1 lesion with angiographic diameter stenosis >50% with no TCFA lesions in the most severely narrowed native coronary artery (target vessel). TCFA was defined as a lipidic plaque with the thinnest FCT <75 mm and maximum lipid arc >180°.
  • Rule out elevation of troponin or myocardial enzymology.

Vulnerable plaque group:

  • Have been clinically stable for at least 6 months.
  • Presence of ≥1 lesion with angiographic diameter stenosis >50% with TCFA lesions in the most severely narrowed native coronary artery (target vessel).
  • Rule out elevation of troponin or myocardial enzymology.

Plaque rupture group:

  • Persistent chest pain for 30 minutes, arrival at the hospital within 24 hours from symptom onset. ST-segment elevation of >0.1 mV in ≥2 contiguous leads or new-onset left bundle branch block, and high sensitive Troponin T or I or CK/CK-MB above upper reference value.
  • Exist clearly identified culprit lesion.
  • Plaque rupture was defined by the presence of a discontinuity of the fibrous cap with a cavity formed inside the plaque.

Plaque erosion group:

  • Persistent chest pain for 30 minutes, arrival at the hospital within 24 hours from symptom onset. ST-segment elevation of >0.1 mV in ≥2 contiguous leads or new-onset left bundle branch block, and high sensitive Troponin T or I or CK/CK-MB above upper reference value.
  • Exist clearly identified culprit lesion.
  • Plaque erosion was defined by the presence of the attached thrombus overlying the intact fibrous cap of the atherosclerotic plaque, luminal surface irregularity at the culprit lesion in the absence of thrombus, or attenuation of the underlying plaque by thrombus without superficial lipid or calcium at the site of the thrombus.

Exclusion criteria

  • Cardiogenic shock or circulatory depression，life-threatening arrhythmia.
  • Known systolic heart failure with LVEF ≤30%.
  • Severe systemic diseases (end-stage renal disease, serious liver dysfunction, chronic active inflammatory diseases, active oncologic diseases, autoimmune diseases).
  • Septicemia, acute inflammatory event with fever.
  • Patients with organ transplants or patients on the waiting list for an organ transplant.
  • Previous CABG treatment, PCI treatment of the target vessel, and PCI treatment of non-target vessels within 1 year.
  • Thrombolysis before PCI.
  • Stenosis of the left main artery ≥50%.
  • Characteristics rendering high-quality OCT imaging unlikely such as chronic total occlusion, pronounced tortuosity, heavily calcified vessels.
  • Infarcted vessel with a diameter >4mm or <2.5mm.
  • "No-reflow" (TIMI 0-1) after thrombus aspiration or predilatation.
  • Other subjects deemed unsuitable for study by investigators.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

China · 2 centers
  • The Second Affiliated Hospital of Harbin Medical University — Harbin
  • China-Japan Union Hospital of Jilin — Changchun

Identifiers

NCT: NCT06489119 · KY2024-084

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗